Literature DB >> 1786619

In vitro sensitivity of southern African reference isolates of Plasmodium falciparum to chloroquine and pyrimethamine.

J A Freese1, M B Markus, J Golenser.   

Abstract

The in vitro sensitivity to chloroquine and pyrimethamine of 19 culture-adapted southern African reference isolates of Plasmodium falciparum was determined using a 48-hour assay. Four isolates collected in KwaZulu, Natal, were sensitive to chloroquine, and one of these was sensitive to the drug in vivo. Eight isolates from KwaZulu or Mozambique were resistant to chloroquine in vitro. Six of these isolates were chloroquine-resistant in varying degrees in vivo. Four of five isolates from north-eastern Transvaal and two clinically chloroquine-resistant Malawian isolates were resistant to chloroquine in vitro. A wide range of pyrimethamine susceptibilities was detected (0.01 mumol/l to greater than 3.0 mumol/l), although most isolates were inhibited at 0.1 mumol/l, indicating a low level of resistance. These results confirm the presence of both chloroquine and pyrimethamine resistance in the endemic areas of South Africa. This has serious implications for the prophylaxis and treatment of P. falciparum malaria in South Africa.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1786619      PMCID: PMC2393318     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  18 in total

1.  Typing of southern African isolates of Plasmodium falciparum using monoclonal antibodies.

Authors:  J A Freese; M B Markus; J Golenser
Journal:  Am J Trop Med Hyg       Date:  1990-07       Impact factor: 2.345

2.  Enzyme typing of southern African isolates of Plasmodium falciparum by polyacrylamide gel electrophoresis.

Authors:  J A Freese; M B Markus
Journal:  Trans R Soc Trop Med Hyg       Date:  1990 Jul-Aug       Impact factor: 2.184

3.  In vitro demonstration of pyrimethamine resistance of "wild" Plasmodium falciparum in The Gambia.

Authors:  M E Smalley; J Brown
Journal:  Trans R Soc Trop Med Hyg       Date:  1982       Impact factor: 2.184

4.  Clinical drug-resistant falciparum malaria acquired from cultured parasites.

Authors:  J B Jensen; T C Capps; J M Carlin
Journal:  Am J Trop Med Hyg       Date:  1981-05       Impact factor: 2.345

5.  In vivo and in vitro chloroquine-resistant falciparum malaria in Venda. A case report.

Authors:  D J Bac; G A Cox; M Isaäcson
Journal:  S Afr Med J       Date:  1985-06-08

6.  Concomitant resistance to pyrimethamine and cycloguanil of chloroquine-resistant falciparum malaria from East Africa: an in vitro study of 12 isolates.

Authors:  A Schapira
Journal:  Trans R Soc Trop Med Hyg       Date:  1984       Impact factor: 2.184

Review 7.  Malaria 1984. Part II. Drug-resistant malaria.

Authors:  F H Spracklen; R G Whittaker
Journal:  S Afr Med J       Date:  1984-08-11

8.  Plasmodium falciparum in culture: establishment of additional strains.

Authors:  J B Jensen; W Trager
Journal:  Am J Trop Med Hyg       Date:  1978-07       Impact factor: 2.345

9.  Comparison of in vitro pyrimethamine assays and in vivo response to sulphadoxine-pyrimethamine in Plasmodium falciparum from Papua New Guinea.

Authors:  G Lamont; B Darlow
Journal:  Trans R Soc Trop Med Hyg       Date:  1982       Impact factor: 2.184

10.  Pyrimethamine sensitivity in Plasmodium falciparum: determination in vitro by a modified 48-hour test.

Authors:  P Nguyen-Dinh; D Payne
Journal:  Bull World Health Organ       Date:  1980       Impact factor: 9.408

View more
  2 in total

1.  Analysis of P-glycoprotein expression in purified parasite plasma membrane and food vacuole from Plasmodium falciparum.

Authors:  Laurence M Elandaloussi; Meinrad Lindt; Malcolm Collins; Peter J Smith
Journal:  Parasitol Res       Date:  2006-05-19       Impact factor: 2.289

2.  Reversal of chloroquine resistance in Plasmodium falciparum using combinations of chemosensitizers.

Authors:  D A van Schalkwyk; J C Walden; P J Smith
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.